

Brant A Inman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5296276/brant-a-inman-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

5,161
citations

37
h-index

69
g-index

176
ext. papers

6,113
ext. citations

4.3
avg, IF

5.32
L-index

#	Paper	IF	Citations
129	Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.. <i>European Urology</i> , 2022 ,	10.2	3
128	517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors 2021 , 9, A547-A547		
127	Plasmonic Gold Nanostars for Immuno Photothermal Nanotherapy to Treat Cancers and Induce Long-Term Immunity. <i>Bioanalysis</i> , 2021 , 173-190	0.5	
126	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021 , 127, 2204-2212	6.4	12
125	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology, The</i> , 2021 , 22, 107-117	17.7	53
124	Diet and Exercise Are not Associated with Skeletal Muscle Mass and Sarcopenia in Patients with Bladder Cancer. <i>European Urology Oncology</i> , 2021 , 4, 237-245	6.7	2
123	Editorial Comment. <i>Journal of Urology</i> , 2021 , 205, 390-391	2.5	
122	Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer. <i>Nanophotonics</i> , 2021 , 10, 3295-3302	6.3	3
121	Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 498.e13-498.e20	2.8	2
120	Assessments of frailty in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 698-705	2.8	5
119	Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020 , 3, 318-340	6.7	14
118	The nephroureterectomy: a review of technique and current controversies. <i>Translational Andrology and Urology</i> , 2020 , 9, 3168-3190	2.3	
117	Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor. <i>Case Reports in Urology</i> , 2020 , 2020, 8881841	0.5	2
116	Heated Intravesical Chemotherapy: Biology and Clinical Utility. <i>Urologic Clinics of North America</i> , 2020 , 47, 55-72	2.9	5
115	Partitioning of time trends in prevalence and mortality of bladder cancer in the United States. <i>Annals of Epidemiology</i> , 2020 , 47, 25-29	6.4	3
114	Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. <i>International Journal of Hyperthermia</i> , 2020 , 37, 854-860	3.7	9
113	Hyperthermia Improves Solubility of Intravesical Chemotherapeutic Agents. <i>Bladder Cancer</i> , 2020 , 6, 461-470	1	1

112	Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 330-337	1.7	2
111	Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. <i>European Urology Focus</i> , 2020 , 6, 620-622	5.1	6
110	Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute's Initial Experience. <i>Oncology</i> , 2020 , 34, 156-162	1.8	
109	Impact of an enhanced recovery pathway on length of stay and complications in elective radical cystectomy: a before and after cohort study. <i>Perioperative Medicine (London, England)</i> , 2019 , 8, 9	2.8	12
108	A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 428-437	6.2	24
107	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1790-1798	13.4	5
106	Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. <i>Journal of Urology</i> , 2019 , 202, 920-926	2.5	8
105	PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis. <i>Bladder Cancer</i> , 2019 , 5, 211-223	1	4
104	Urologic Malignancies 2019 , 115-133		
103	Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 338.e1-338.e11	2.8	17
102	Trends in Urological Referral Patterns: A Study of Community and University Urologists in the United States. <i>Urology Practice</i> , 2018 , 5, 480-488	0.8	1
101	Urine Cytology and Existing Urinary Biomarkers for Bladder Cancer. <i>Molecular Pathology Library</i> , 2018 , 137-155		
100	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. <i>European Urology</i> , 2018 , 73, 40-50	10.2	69
99	Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. <i>Bladder Cancer</i> , 2018 , 4, 429-440	1	5
98	Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. <i>Core Evidence</i> , 2018 , 13, 1-12	4.9	6
97	Dietary patterns and health-related quality of life in bladder cancer survivors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 469.e21-469.e29	2.8	3
96	What potential does plasmonics-amplified synergistic immuno photothermal nanotherapy have for treatment of cancer?. <i>Nanomedicine</i> , 2018 , 13, 139-144	5.6	8
95	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 1041-1053	7.3	128

94	Anticipatory Positive Urine Tests for Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1747-1753	3.1	16
93	Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer. <i>Cancer Biomarkers</i> , 2017 , 18, 381-387	3.8	14
92	Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1886-1890	10.4	
91	Physical activity patterns and associations with health-related quality of life in bladder cancer survivors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 540.e1-540.e6	2.8	11
90	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1240-1267	7.3	172
89	Intravesical rAd-IFN γ /Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3410-3416	2.2	86
88	Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers. <i>Scientific Reports</i> , 2017 , 7, 8606	4.9	82
87	MP65-08 HEAT-TARGETED DRUG DELIVERY USING THE COMBAT BRS DEVICE FOR TREATING BLADDER CANCER. <i>Journal of Urology</i> , 2017 , 197,	2.5	2
86	MP98-09 SYNERGISTIC IMMUNO-PHOTOTHERMAL NANOTHERAPY (SYMPHONY): A NOVEL TREATMENT FOR LOCALIZED AND METASTATIC BLADDER CANCER. <i>Journal of Urology</i> , 2017 , 197,	2.5	2
85	Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. <i>European Urology</i> , 2016 , 70, 714-717	10.2	7
84	Lifestyle factors and health-related quality of life in bladder cancer survivors: a systematic review. <i>Journal of Cancer Survivorship</i> , 2016 , 10, 874-82	5.1	13
83	Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? <i>European Urology</i> , 2016 , 69, 221-11	10.2	184
82	The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient. <i>BMC Urology</i> , 2016 , 16, 30	2.2	24
81	High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 407-14	2.8	5
80	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1213-1224	7.3	73
79	MP04-06 A PROSPECTIVE RANDOMIZED TRIAL OF DIETARY CARBOHYDRATE RESTRICTION FOR MEN INITIATING ANDROGEN DEPRIVATION THERAPY: CARBOHYDRATE AND PROSTATE STUDY I (CAPS1). <i>Journal of Urology</i> , 2016 , 195,	2.5	2
78	Reporting Bias Leading to Discordant Venous Thromboembolism Rates in the United States Versus Non-US Countries Following Radical Cystectomy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2016 , 2, 189-196	5.1	6
77	A systematic review of regional hyperthermia therapy in bladder cancer. <i>International Journal of Hyperthermia</i> , 2016 , 32, 381-9	3.7	34

76	Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study. <i>British Journal of Cancer</i> , 2015 , 112, 825-31	8.7	26
75	Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 387.e1-6	2.8	21
74	Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?. <i>World Journal of Urology</i> , 2015 , 33, 1309-13	4	36
73	It May Be Time to Abandon Urine Tests for Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1163-6	7.3	10
72	Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency. <i>Thrombosis Research</i> , 2014 , 133, 629-33	8.2	8
71	A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. <i>International Journal of Hyperthermia</i> , 2014 , 30, 166-70	3.7	29
70	A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. <i>International Journal of Hyperthermia</i> , 2014 , 30, 171-5	3.7	51
69	Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer. <i>International Journal of Hyperthermia</i> , 2014 , 30, 176-83	3.7	24
68	Clinical performance and utility of a DNA methylation urine test for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 51.e21-6	2.8	22
67	Penile Cancer 2014 , 305-310		
66	Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 812-26	2.8	6
65	Words of wisdom. Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. <i>European Urology</i> , 2013 , 64, 171-8	10.2	
64	Note on "simulation optimization of PSA-threshold based prostate cancer screening policies". <i>Health Care Management Science</i> , 2013 , 16, 377-8	4	
63	Magnetic fluid hyperthermia for bladder cancer: a preclinical dosimetry study. <i>International Journal of Hyperthermia</i> , 2013 , 29, 835-44	3.7	38
62	Novel immunotherapeutic strategies in development for renal cell carcinoma. <i>European Urology</i> , 2013 , 63, 881-9	10.2	31
61	Contemporary epidemiological trends in complex congenital genitourinary anomalies. <i>Journal of Urology</i> , 2013 , 190, 1590-5	2.5	67
60	The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment. <i>International Journal of Hyperthermia</i> , 2013 , 29, 206-10	3.7	49
59	Preclinical Dosimetry of Magnetic Fluid Hyperthermia for Bladder Cancer. <i>Proceedings of SPIE</i> , 2013 , 8584, 1656985	1.7	3

58	Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. <i>BioMed Research International</i> , 2013 , 2013, 262313	3	33
57	Increasing dwell time of mitomycin C in the upper tract with a reverse thermosensitive polymer. <i>Journal of Endourology</i> , 2013 , 27, 288-93	2.7	5
56	Penile cancer: Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 594-615	7.3	119
55	Bladder cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 446-75	7.3	271
54	Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 477-84	7.3	68
53	Report of a rare fistula between a Studer neobladder and external iliac artery. <i>Canadian Urological Association Journal</i> , 2013 , 7, E645-7	1.2	5
52	An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time. <i>BJU International</i> , 2012 , 110, 375-81	5.6	4
51	Simulation optimization of PSA-threshold based prostate cancer screening policies. <i>Health Care Management Science</i> , 2012 , 15, 293-309	4	19
50	Bilateral renal cell carcinoma in a child. <i>Urology</i> , 2012 , 80, 430-3	1.6	1
49	Soluble B7-H1: differences in production between dendritic cells and T cells. <i>Immunology Letters</i> , 2012 , 142, 78-82	4.1	86
48	Outcomes of metallic stents for malignant ureteral obstruction. <i>Journal of Urology</i> , 2012 , 188, 851-5	2.5	45
47	Optimization of PSA screening policies: a comparison of the patient and societal perspectives. <i>Medical Decision Making</i> , 2012 , 32, 337-49	2.5	31
46	Optimization of Prostate Biopsy Referral Decisions. <i>Manufacturing and Service Operations Management</i> , 2012 , 14, 529-547	4.6	50
45	Miniature microwave applicator for murine bladder hyperthermia studies. <i>International Journal of Hyperthermia</i> , 2012 , 28, 456-65	3.7	16
44	Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. <i>Journal of Endourology</i> , 2011 , 25, 377-84	2.7	26
43	Dynamic prediction of metastases after radical prostatectomy for prostate cancer. <i>BJU International</i> , 2011 , 108, 1762-8	5.6	6
42	The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. <i>European Urology</i> , 2011 , 60, 81-93	10.2	134
41	CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. <i>Expert Review of Vaccines</i> , 2011 , 10, 733-42	5.2	30

40	Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. <i>Clinical Cancer Research</i> , 2011 , 17, 1915-23	12.9	235
39	Imaging tumors of the penis and urethra. <i>Urologic Clinics of North America</i> , 2010 , 37, 353-67	2.9	27
38	Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. <i>Pediatrics</i> , 2010 , 125, 1010-9	7.4	114
37	Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. <i>BMC Cancer</i> , 2010 , 10, 531	4.8	29
36	Hyperthermia as a treatment for bladder cancer. <i>Oncology</i> , 2010 , 24, 1149-55	1.8	17
35	Early detection of prostate cancer local recurrence by urinary prostate-specific antigen. <i>Canadian Urological Association Journal</i> , 2009 , 3, 213-7	1.2	5
34	Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. <i>Cancer</i> , 2009 , 115, 2853-62	6.4	43
33	Obstructive Sleep Apnea Associated With Erectile Dysfunction and Cardiovascular Disease Reply <input type="checkbox"/> <i>Mayo Clinic Proceedings</i> , 2009 , 84, 562	6.4	1
32	A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 108-13	6.4	319
31	Outcome analysis of urethral wall stent insertion with artificial urinary sphincter placement for severe recurrent bladder neck contracture following radical prostatectomy. <i>Journal of Urology</i> , 2009 , 181, 1236-41	2.5	42
30	Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma 2009 , 367-403		
29	Reassessing the diagnostic yield of saturation biopsy of the prostate. <i>European Urology</i> , 2008 , 53, 976-81	10.2	48
28	Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. <i>Journal of Urology</i> , 2008 , 179, 1830-7; discussion 1837	2.5	61
27	Utility of dextranomer/hyaluronic acid injection in setting of bladder and ureteral anomalies. <i>Urology</i> , 2008 , 71, 435-8	1.6	12
26	Unilateral vesicoureteral reflux: does endoscopic injection based on the cystoscopic appearance of the ureteral orifice decrease the incidence of de-novo contralateral reflux?. <i>Journal of Pediatric Urology</i> , 2008 , 4, 260-4	1.5	2
25	Sacral neuromodulation for the dysfunctional elimination syndrome: a single center experience with 20 children. <i>Journal of Urology</i> , 2008 , 180, 306-11; discussion 311	2.5	69
24	Re: Endoscopic treatment of vesicoureteral reflux associated with paraureteral diverticula in children. W. H. Cerwinka, H. C. Scherz and A. J. Kirsch. <i>J Urol</i> 2007; 178: 1469-1473. <i>Journal of Urology</i> , 2008 , 179, 1205; author reply 1205	2.5	0
23	Increased optical magnification from 2.5x to 4.3x with technical modification lowers the positive margin rate in open radical retropubic prostatectomy. <i>Journal of Urology</i> , 2008 , 179, 130-5	2.5	37

22	Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. <i>Journal of Immunology</i> , 2008 , 180, 3578-84	5.3	25
21	Is the location of a positive surgical margin after radical prostatectomy important for prognosis?. <i>Nature Reviews Urology</i> , 2008 , 5, 476-7		
20	After radical retropubic prostatectomy insignificant prostate cancer has a risk of progression similar to low-risk significant cancer. <i>BJU International</i> , 2008 , 101, 170-4	5.6	30
19	Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. <i>Cancer</i> , 2008 , 113, 1544-51	6.4	35
18	B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. <i>Cancer Research</i> , 2007 , 67, 7893-900	10.1	198
17	Urachal anomalies: a longitudinal study of urachal remnants in children and adults. <i>Journal of Urology</i> , 2007 , 178, 1615-8	2.5	116
16	Multivariate comparison of the efficacy of intraureteral versus subtrigonal techniques of dextranomer/hyaluronic acid injection. <i>Journal of Urology</i> , 2007 , 178, 1702-5; discussion 1705-6	2.5	27
15	Does preoperative topical antimicrobial scrub reduce positive surgical site culture rates in men undergoing artificial urinary sphincter placement?. <i>Journal of Urology</i> , 2007 , 178, 1328-32; discussion 1332	2.5	25
14	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. <i>Cancer</i> , 2007 , 109, 1499-505	6.4	322
13	Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. <i>Cancer</i> , 2007 , 110, 1708-14	6.4	31
12	Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. <i>Journal of Immunology</i> , 2007 , 179, 2860-9	5.3	61
11	Costimulation, coinhibition and cancer. <i>Current Cancer Drug Targets</i> , 2007 , 7, 15-30	2.8	79
10	The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. <i>Urology</i> , 2007 , 70, 1064-8	1.6	82
9	Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. <i>Cancer</i> , 2006 , 107, 521-9	6.4	97
8	Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. <i>Cancer</i> , 2006 , 107, 712-20	6.4	203
7	Re: Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J. S. Jones, A. Patel, L. Schoenfield, J. C. Rabets, C. D. Zippe and C. Magi-Galluzzi. <i>J Urol</i> , 175: 485-488, 2006. <i>Journal of Urology</i> , 2006 , 176, 1252-3; author reply 1253	2.5	
6	Re: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. <i>Journal of Urology</i> , 2006 , 175, 1960; author reply 1960-1	2.5	2
5	Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. <i>Urology</i> , 2006 , 68, 604-8	1.6	8

4	Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. <i>European Urology</i> , 2005 , 47, 695-702	10.2	23
3	Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients. <i>Journal of Urology</i> , 2003 , 170, 1888-91	2.5	47
2	Re: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. <i>Journal of Urology</i> , 2003 , 170, 2392; author reply 2392	2.5	
1	Microchimerism in sensitized renal patients. <i>Transplantation</i> , 1999 , 67, 1381-3	1.8	14